The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare analysts Datamonitor Healthcare.
The market is currently valued at $12 billion, but is expected to grow driven by the continued uptake of novel oral therapies. Datamonitor Healthcare says that the MS market in the USA, Japan and five major EU markets is estimated to expand by more than $6 billion at a compound annual growth rate of 7.4%, peaking at $18.3 billion in 2018.
Novel therapies expected to become blockbusters
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze